HMMR and prostate cancer: Recently, a growing number of evidence suggests that HMMR is overexpressed in solid tumors and hematological malignancies, including prostate cancer, bladder cancer, gastric cancer, breast cancer, and leukemia [19–22], and it is not known whether HMMR contributes to HCC prognosis.